apatinib + PD-1 inhibitor (Henan Cancer Hospital)

This combination therapy regimen involves the use of **apatinib**, a small-molecule tyrosine kinase inhibitor (TKI), alongside various **PD-1 inhibitors** (such as camrelizumab, sintilimab, or pembrolizumab). Apatinib functions by selectively inhibiting the **vascular endothelial growth factor receptor 2 (VEGFR-2)**, thereby suppressing tumor angiogenesis and potentially modulating the tumor microenvironment to be more receptive to immunotherapy. The PD-1 inhibitors are monoclonal antibodies that block the interaction between the PD-1 receptor on T-cells and its ligands (PD-L1/PD-L2), effectively "releasing the brakes" on the immune system to attack cancer cells. This specific combination is being evaluated in Phase II clinical trials at **Henan Cancer Hospital** for patients with advanced or metastatic **gastric cancer** or gastroesophageal junction cancer who have progressed after standard second-line treatments.

Other names

apatinib plus PD-1 inhibitorapatinib and PD-1 inhibitor combination therapy